What is Biodesix?
Biodesix operates as a data-driven diagnostic solutions company, primarily focused on the United States market. The company's core offerings include blood-based lung tests, such as the Nodify XL2 and Nodify CDT tests, which are part of the Nodify Lung Nodule Risk Assessment strategy. These tests aim to evaluate the risk of lung cancer and assist physicians in determining the most appropriate treatment pathways by reclassifying the risk of malignancy in patients with suspicious lung nodules. Additionally, Biodesix provides GeneStrat ddPCR and NGS, along with VeriStrat tests, designed for lung cancer diagnosis. These advanced diagnostics measure tumor mutations and the patient's immune system status to establish prognosis and guide treatment decisions, positioning Biodesix as a key player in precision oncology diagnostics.
How much funding has Biodesix raised?
Biodesix has raised a total of $268.4M across 11 funding rounds:
Series C
$7.1M
Series D
$20M
Series E
$38M
Series F
$22M
Debt
$23M
Debt
$2M
Stock Offering
$72M
Stock Offering
$16.3M
Stock Offering
$50M
Series C (2010): $7.1M, investors not publicly disclosed
Series D (2011): $20M, investors not publicly disclosed
Series E (2015): $38M, investors not publicly disclosed
Series F (2016): $22M, investors not publicly disclosed
Debt (2018): $23M led by Innovatus Capital Partners
Debt (2020): $2M supported by PPP
Stock Issuance/Offering (2020): $72M featuring Undisclosed
Stock Issuance/Offering (2022): $16.3M, investors not publicly disclosed
Stock Issuance/Offering (2022): $50M with participation from Lincoln Park Capital
Key Investors in Biodesix
Innovatus Capital Partners
Innovatus Capital Partners is a firm specializing in long-term capital investments, focusing on opportunities arising from market volatility and disruptions. They target asset-based investments with strong cash flow and possess expertise in financial engineering and business development.
Lincoln Park Capital
Lincoln Park Capital is an investment group and asset management firm that specializes in opportunistic investing across public and private companies. They focus on growth and partnership opportunities, with investment types including private equity and venture capital.
What's next for Biodesix?
With the recent major strategic investment and substantial overall capital raised, Biodesix is poised for significant advancements. The company's focus on blood-based diagnostics for lung cancer risk assessment and treatment guidance aligns with the growing demand for non-invasive and precise diagnostic tools in oncology. This funding will likely accelerate the commercialization of its existing products, support further research and development into new diagnostic markers, and potentially expand its market reach. The company's trajectory suggests a continued emphasis on leveraging data analytics and advanced molecular diagnostics to improve patient outcomes and support clinical decision-making in lung cancer care.
See full Biodesix company page
